Cabio Biotech (Wuhan) Full Year 2024 Earnings: Beats Expectations

Simply Wall St · 03/29 01:03

Cabio Biotech (Wuhan) (SHSE:688089) Full Year 2024 Results

Key Financial Results

  • Revenue: CN¥555.6m (up 25% from FY 2023).
  • Net income: CN¥124.2m (up 36% from FY 2023).
  • Profit margin: 22% (up from 21% in FY 2023). The increase in margin was driven by higher revenue.
  • EPS: CN¥0.74 (up from CN¥0.54 in FY 2023).
earnings-and-revenue-growth
SHSE:688089 Earnings and Revenue Growth March 29th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Cabio Biotech (Wuhan) Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 4.3%. Earnings per share (EPS) also surpassed analyst estimates by 5.7%.

Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China.

Performance of the Chinese Chemicals industry.

The company's shares are down 2.7% from a week ago.

Risk Analysis

Before you take the next step you should know about the 2 warning signs for Cabio Biotech (Wuhan) that we have uncovered.